Aridis Pharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary

Aridis Pharmaceuticals

23/05/2023 24:50

* Aridis Pharmaceuticals Inc  ARDS.OQ  reported a quarterly
adjusted loss of 60 cents​​ per share for the quarter ended in
December. The mean expectation of three analysts for the quarter
was for a loss of 41 cents per share.
    * Revenue rose 112.8% to $1.21 million from a year ago;
analysts
expected $308.33 thousand. 
    * Aridis Pharmaceuticals Inc's reported EPS for the quarter
was a
loss of 60 cents​.
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Aridis Pharmaceuticals Inc shares had fallen by 36.3% this
quarter and lost 83.1% so far this year.
    * The company reported a quarterly loss of $10.5 million.
    * Wall Street's median 12-month price target for Aridis
Pharmaceuticals Inc is $6.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data May
22 at 11:49 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2022      -0.41          -0.60          Missed
 Sep. 30 2022      -0.17          -0.47          Missed
 Jun. 30 2022      -0.06          -0.45          Missed
 Mar. 31 2022      -0.51          -0.44          Beat